Skip to main content
Watch Insiders
KNSAHealthcare

Kiniksa Pharmaceuticals Ltd (KNSA) Insider Trading

In the last 90 days, 1 Kiniksa Pharmaceuticals Ltd (KNSA) insider reported no open-market purchases and 1 sale totaling $369,380. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Sep 3, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Sep 3, 2026Michael R MegnaCHIEF ACCOUNTING OFFICERSale4,600$80.30$369,380
Jul 29, 2026G Bradley ColeDirectorSale3,673$81.43$299,092
May 1, 2026John F. PaoliniCHIEF MEDICAL OFFICERSale58,424$53.71$3,137,825
May 1, 2026Sanj K PatelCHAIRMAN & CEOSale48,565$54.02$2,623,481
Apr 30, 2026Sanj K PatelCHAIRMAN & CEOSale508,339$51.96$26,415,226
Apr 28, 2026Barry D QuartDirectorSale13,099$50.10$656,260

Common questions

KNSA insider trading FAQ

Are KNSA insiders buying or selling?
Over the last 90 days, KNSA insiders were net sellers, reporting $0.00 of open-market purchases and $369,380 of sales.
When was the last KNSA insider purchase?
No open-market insider purchase of Kiniksa Pharmaceuticals Ltd stock was reported in the last 90 days.
Where does KNSA insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Kiniksa Pharmaceuticals Ltd officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.